JP2025148550A5 - - Google Patents
Info
- Publication number
- JP2025148550A5 JP2025148550A5 JP2025120522A JP2025120522A JP2025148550A5 JP 2025148550 A5 JP2025148550 A5 JP 2025148550A5 JP 2025120522 A JP2025120522 A JP 2025120522A JP 2025120522 A JP2025120522 A JP 2025120522A JP 2025148550 A5 JP2025148550 A5 JP 2025148550A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- concentration
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828859P | 2019-04-03 | 2019-04-03 | |
| US62/828,859 | 2019-04-03 | ||
| US201962832032P | 2019-04-10 | 2019-04-10 | |
| US62/832,032 | 2019-04-10 | ||
| PCT/US2020/026669 WO2020206320A1 (en) | 2019-04-03 | 2020-04-03 | Formulations of protein molecules comprising iduronate 2-sulfatase |
| JP2021558657A JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Division JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025148550A JP2025148550A (ja) | 2025-10-07 |
| JP2025148550A5 true JP2025148550A5 (enExample) | 2026-05-21 |
Family
ID=70457135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Active JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
| JP2025120522A Pending JP2025148550A (ja) | 2019-04-03 | 2025-07-17 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Active JP7715635B2 (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220184186A1 (enExample) |
| EP (1) | EP3947661A1 (enExample) |
| JP (2) | JP7715635B2 (enExample) |
| KR (1) | KR20220004651A (enExample) |
| CN (1) | CN113785054A (enExample) |
| AU (1) | AU2020252554A1 (enExample) |
| BR (1) | BR112021019520A2 (enExample) |
| CA (1) | CA3134538A1 (enExample) |
| MA (1) | MA71657A (enExample) |
| MX (1) | MX2021011612A (enExample) |
| WO (1) | WO2020206320A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ756763A (en) | 2017-02-17 | 2023-04-28 | Denali Therapeutics Inc | Engineered transferrin receptor binding polypeptides |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| JP7235770B2 (ja) | 2018-05-10 | 2023-03-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 |
| PH12021552002A1 (en) | 2019-02-20 | 2022-09-19 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| EP3699923A1 (de) * | 2019-02-20 | 2020-08-26 | Fresenius Medical Care Deutschland GmbH | Absicherungsmechanismus fuer den betrieb von medizinischen geraeten unter verwendung von verbrauchsgegenstaenden im umfeld einer dialyse |
| MX2022007486A (es) | 2019-12-23 | 2022-06-29 | Denali Therapeutics Inc | Variantes de progranulina. |
| KR20220131246A (ko) | 2020-01-13 | 2022-09-27 | 데날리 테라퓨틱스 인크. | 항-trem2 항체 및 이의 사용 방법 |
| AU2021362209B2 (en) | 2020-10-14 | 2026-02-12 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| US20250018015A1 (en) | 2021-07-23 | 2025-01-16 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| KR20230134822A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제 |
| TW202542190A (zh) * | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2485761T1 (sl) | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| KR20180071193A (ko) * | 2016-12-19 | 2018-06-27 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체 |
| NZ756763A (en) | 2017-02-17 | 2023-04-28 | Denali Therapeutics Inc | Engineered transferrin receptor binding polypeptides |
| WO2019022563A2 (ko) * | 2017-07-28 | 2019-01-31 | 한미약품 주식회사 | 이두로네이트 2-설파타제 결합체 |
| MX2020002918A (es) * | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
-
2020
- 2020-04-03 CA CA3134538A patent/CA3134538A1/en active Pending
- 2020-04-03 WO PCT/US2020/026669 patent/WO2020206320A1/en not_active Ceased
- 2020-04-03 KR KR1020217035336A patent/KR20220004651A/ko active Pending
- 2020-04-03 BR BR112021019520A patent/BR112021019520A2/pt unknown
- 2020-04-03 US US17/600,527 patent/US20220184186A1/en active Pending
- 2020-04-03 CN CN202080033104.6A patent/CN113785054A/zh active Pending
- 2020-04-03 EP EP20721359.6A patent/EP3947661A1/en active Pending
- 2020-04-03 JP JP2021558657A patent/JP7715635B2/ja active Active
- 2020-04-03 MX MX2021011612A patent/MX2021011612A/es unknown
- 2020-04-03 AU AU2020252554A patent/AU2020252554A1/en active Pending
- 2020-04-03 MA MA71657A patent/MA71657A/fr unknown
-
2025
- 2025-07-17 JP JP2025120522A patent/JP2025148550A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099628A5 (enExample) | ||
| JP2544968B2 (ja) | 高イオン性濃度媒体中の血漿及び組換え蛋白処方物 | |
| CN1523997B (zh) | 稳定的白介素2 | |
| JP2024099682A5 (enExample) | ||
| JP5695318B2 (ja) | 組織傷害の修復におけるストロマ細胞由来因子１のプロテアーゼ耐性変異体 | |
| JP3100005B2 (ja) | ヒト免疫不全ウィルス感染・増殖抑制剤 | |
| JP2022526799A5 (enExample) | ||
| JP2023113751A5 (enExample) | ||
| JP2003500456A (ja) | 角質細胞増殖因子−２製剤 | |
| JPH0558000B2 (enExample) | ||
| CN116323649A (zh) | 膜联蛋白a1 n-末端肽的制剂和方法 | |
| JP2022151814A5 (enExample) | ||
| JP2024540377A5 (enExample) | ||
| JPS59181224A (ja) | 安定なインタ−フエロン製剤の製法 | |
| US5824305A (en) | Method of treating diseases mediated by cyclic nucleotide pathways with purified stem bromelain protease | |
| JP2024522855A5 (enExample) | ||
| CN112390884B (zh) | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 | |
| JP2025512749A5 (enExample) | ||
| JP2024526820A5 (enExample) | ||
| JP2023523253A5 (enExample) | ||
| KR20230019089A (ko) | 바이러스 감염을 치료하기 위한 계면활성제 단백질 d의 용도 | |
| JP2024538091A5 (enExample) | ||
| IE903479A1 (en) | Stabilized Leukocyte-Interferons | |
| JPH04208228A (ja) | インシュリン様成長因子ｉの乾燥製剤 | |
| JPH10330283A (ja) | 消化管組織再生賦活剤 |